en · de · es · pt
aod-9604-notes.peptides6608.com › Blog › Mechanism And Regulatory Status — Background and Details

Mechanism And Regulatory Status — Background and Details

By Editorial Desk · published 2026-05-28 · last reviewed 2026-06-13 · Blog

synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-06-13. Numbers and descriptions here follow the published literature rather than marketing material.

Mechanism and Regulatory Status

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Background and Molecular Identity

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.

Aod-9604 at a glance

PropertyValueNotes
Typical storage temperature-20 °CLyophilized peptide; protect from moisture and light.
Typical analytical methodHPLC and mass spectrometryUsed to confirm identity and estimate purity.
Common synonymsAOD9604; hGH 176-191Naming varies by supplier and publication.
Disulfide bondsOneAffects folded structure and stability.
Typical research purity≥95%Value depends on supplier and analytical method.

Handling, Analysis, and Quality Control

AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.

Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.

Related pages on this site

Research and Regulatory Status

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Background from the literature

== Scope of Services == Girteka specializes in temperature-controlled and high-value cargo transportation across the continent, delivering a wide range of goods, including fresh, chilled, frozen, and processed foods. Focusing on the following operational segments within road transportation:

The structure of the U.S. healthcare system, in which people not qualifying for government programs are required to obtain private insurance, favors prescribing drugs over more expensive therapies. According to Professor Judith Feinberg, "Most insurance, especially for poor people, won't pay for anything but a pill." While the rates of opioid prescriptions increased between 2001 and 2010, the prescription of non-opioid pain relievers (aspirin, ibuprofen, etc.) decreased from 38% to 29% of ambulatory visits in the same period. The annual opioid prescribing rates have been slowly decreasing since 2012, but the number is still high. There were about 58 opioid prescriptions per 100 Americans in 2017. Characteristics of jurisdictions with a greater number of opioid prescriptions per resident include small cities or large towns, cities with more dentists and primary care doctors per capita, cities with a higher percentage of white residents, cities with a higher uninsured/unemployment rate, and cities with more residents who have diabetes, arthritis, or a disability. Studies have been conducted to find out how opioids were primarily acquired. A 2013 national survey indicated that 74% of people who recreationally use opioids acquired their opioids directly from a single doctor, friend, or relative, who received their opioids from a clinician. Among pharmacies, the most prolific distributor was Walgreens, which bought 13 billion oxycodone and hydrocodone pills from 2006 to 2012, about twenty percent of all such pills in US pharmacies.

=== India and Ayurveda === Ayurveda is ancient traditional Indian treatment almost universally incorporated alongside Western medicine as a typical component of medical treatment in India. Although Ayurvedic medicine is often effective, doses can be inconsistent, and may sometimes be contaminated with toxic heavy metals. Some brief examples to follow: Termite is said to cure a variety of diseases, both specific and vague. Typically the mound or a portion of the mound is dug up and the termites and the architectural components of the mound are together ground into a paste which is then applied topically to the affected areas or, more rarely, mixed with water and consumed. This treatment was said to cure ulcers, rheumatic diseases, and anemia. It was also suggested to be a general pain reliever and health improver. The Jatropha Leaf Miner, a lepidopteran which feeds preferentially on Jatropha, is an example of a major insect agricultural pest which is also a medicinal remedy. The larvae, which are also the form of the insect with the greatest economic impact on agriculture, are harvested, boiled, and mashed into a paste which is administered topically and is said to induce lactation, reduce fever, and soothe gastrointestinal tracts.

Sources: en.wikipedia.org

Reference notes

The sucrose lysis test is a diagnostic laboratory test used for diagnosing paroxysmal nocturnal hemoglobinuria (PNH), as well as for hypoplastic anemias and any hemolytic anemia with an unclear cause. The test works by using sucrose, which creates a low ionic strength environment that allows complement to bind to red blood cells. In individuals with PNH, some red blood cells are especially vulnerable to lysis caused by complement. The test may also produce suspicious results in other hematologic conditions, including megaloblastic anemia and autoimmune hemolytic anemia. False-negative results can occur when complement activity is absent in the serum. A simpler alternative called the sugar water test also involves mixing blood with sugar and observing for hemolysis, using the same principle as the sucrose lysis test.

The CompTox Chemicals Dashboard is a freely accessible online database created and maintained by the U.S. Environmental Protection Agency (EPA). The database provides access to multiple types of data including physicochemical properties, environmental fate and transport, exposure, usage, in vivo toxicity, and in vitro bioassay. EPA and other scientists use the data and models contained within the dashboard to help identify chemicals that require further testing and reduce the use of animals in chemical testing. The Dashboard is also used to provide public access to information from EPA Action Plans, e.g. around perfluorinated alkylated substances. Originally titled the Chemistry Dashboard, the first version was released in 2016. The latest release of the database (version 3.0.5) contains manually curated data for over 875,000 chemicals and incorporates the latest data generated from the EPA's Toxicity Forecaster (ToxCast) high-throughput screening program. The Chemicals Dashboard incorporates data from several previous EPA databases into one package including the ToxCast Dashboard, the Endocrine Disruption Screening Program (EDSP) Dashboard and the Chemical and Products Database (CPDat).

=== Europe === In Europe GDP is based on the Commission Directive (EU) 2017/1572 of 15 September 2017 supplementing Directive 2001/83/EC of the European Parliament and of the Council as regards the principles and guidelines of good manufacturing practice for medicinal products for human use. In 2016, the European Medicines Agency adopted the Falsified Medicines Directive (FMD), which requires all pharmaceutical products sold in the EU to feature obligatory “safety features.” This directive is scheduled to launch in the first quarter of 2019. By February 9, 2019, all pharmaceutical companies will be required to connect their internal systems to the EU data repository, which contains the product master data and batch information. This will allow pharmacists and consumers to authenticate their medicines.

Sources: en.wikipedia.org

Reference notes

Other than fat, glucose is stored in most tissues, as an energy resource available within the tissue through glycogenesis which was usually being used to maintain blood glucose levels. Polysaccharides and glycans are made by the sequential addition of monosaccharides by glycosyltransferase from a reactive sugar-phosphate donor such as uridine diphosphate glucose (UDP-Glc) to an acceptor hydroxyl group on the growing polysaccharide. As any of the hydroxyl groups on the ring of the substrate can be acceptors, the polysaccharides produced can have straight or branched structures. The polysaccharides produced can have structural or metabolic functions themselves, or be transferred to lipids and proteins by the enzymes oligosaccharyltransferases.

==== Fossil mammoth tusks ==== Trade in the ivory from the tusks of dead woolly mammoths frozen in the tundra has occurred for 300 years and continues to be legal. Mammoth ivory is used today to make handcrafted knives and similar implements. Mammoth ivory is rare and costly because mammoths have been extinct for millennia, and scientists are hesitant to sell museum-worthy specimens in pieces. Some estimates suggest that 10 million mammoths or more are still buried in Siberia.

Thin basement membrane disease is an autosomal dominant inherited disease characterized by thin glomerular basement membranes on electron microscopy. It is a benign condition that causes persistent microscopic hematuria. This also may cause proteinuria which is usually mild and overall prognosis is excellent.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 approved for weight loss?

No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.

Why is AOD-9604 banned in sports?

The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.

Does AOD-9604 raise growth hormone levels?

It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.

What is AOD-9604?

It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.

Network